Since its founding in 2008, Hemanext has envisioned a world with fewer and better transfusions. In its early years, multiple grants from the U.S. National Institutes of Health (NIH) enabled the company to demonstrate the feasibility of hypoxic RBC storage, develop its first prototype system and conduct in vivo research.
Recent Posts
- Hemanext Inc. Announces New HCPCS Code for “Red Blood Cells, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced, Each Unit.”
- Hemanext Inc. Announces Completion of Post-Market Cancer and Burn Safety Study
- AABB Science Innovation Forum Nov 2023
- Hemanext Inc. Announces a Significant Milestone with FDA Marketing Authorization for Hemanext ONE®
- Hemanext Announces Founder Martin Cannon’s Retirement, Appoints Andrew Dunham as CEO, and Raises Funding for Growth